The VITROS immunodiagnostics products anti-HIV 1+2 assay: A rapid and reliable method for HIV screening

Matthew P. Thompson, Darnely Hidalgo, Anne Kim, M. Qasim Ansari

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: To ensure increased awareness of HIV status by patients, the Centers for Disease Control and Prevention (CDC) has issued new guidelines that greatly expand screening recommendations. The goal of the present study was to assess the overall reliability, sensitivity, specificity, and turnaround time (TAT) of the VITROS Anti-HIV 1+2 Assay (Ortho Clinical Diagnostics, Rochester, NY) in a large community hospital setting. The assay was recently approved by the Food and Drug Administration (FDA). Methods: We compared our current Abbott HIVAB assay (Abbott Laboratories, Abbott Park, IL) with how the VITROS performed on the random access VITROS ECi/ECiQ System in a head-to-head comparison of 298 patient samples and a retrospective comparison of TAT over an 8-month period of utilization. Results: Our data indicate that the VITROS is as sensitive (100%, n=298) and more specific (98% vs 83%) than the Abbott HIVAB and has a faster average TAT (156 minutes vs 1266 minutes). Conclusions: Use of this rapid and reliable assay will lead to greater awareness of HIV status and, hopefully, a decrease in incidence of HIV disease.

Original languageEnglish (US)
Pages (from-to)209-212
Number of pages4
JournalLaboratory Medicine
Volume42
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

HIV-2
Turnaround time
HIV-1
Assays
Screening
HIV
Community Hospital
United States Food and Drug Administration
Centers for Disease Control and Prevention (U.S.)
Disease control
Guidelines
Sensitivity and Specificity
Incidence

Keywords

  • HIV
  • Rapid testing
  • Screening

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The VITROS immunodiagnostics products anti-HIV 1+2 assay : A rapid and reliable method for HIV screening. / Thompson, Matthew P.; Hidalgo, Darnely; Kim, Anne; Ansari, M. Qasim.

In: Laboratory Medicine, Vol. 42, No. 4, 04.2011, p. 209-212.

Research output: Contribution to journalArticle

Thompson, Matthew P. ; Hidalgo, Darnely ; Kim, Anne ; Ansari, M. Qasim. / The VITROS immunodiagnostics products anti-HIV 1+2 assay : A rapid and reliable method for HIV screening. In: Laboratory Medicine. 2011 ; Vol. 42, No. 4. pp. 209-212.
@article{c8604d715c5645ac97a6ee9d6966e567,
title = "The VITROS immunodiagnostics products anti-HIV 1+2 assay: A rapid and reliable method for HIV screening",
abstract = "Background: To ensure increased awareness of HIV status by patients, the Centers for Disease Control and Prevention (CDC) has issued new guidelines that greatly expand screening recommendations. The goal of the present study was to assess the overall reliability, sensitivity, specificity, and turnaround time (TAT) of the VITROS Anti-HIV 1+2 Assay (Ortho Clinical Diagnostics, Rochester, NY) in a large community hospital setting. The assay was recently approved by the Food and Drug Administration (FDA). Methods: We compared our current Abbott HIVAB assay (Abbott Laboratories, Abbott Park, IL) with how the VITROS performed on the random access VITROS ECi/ECiQ System in a head-to-head comparison of 298 patient samples and a retrospective comparison of TAT over an 8-month period of utilization. Results: Our data indicate that the VITROS is as sensitive (100{\%}, n=298) and more specific (98{\%} vs 83{\%}) than the Abbott HIVAB and has a faster average TAT (156 minutes vs 1266 minutes). Conclusions: Use of this rapid and reliable assay will lead to greater awareness of HIV status and, hopefully, a decrease in incidence of HIV disease.",
keywords = "HIV, Rapid testing, Screening",
author = "Thompson, {Matthew P.} and Darnely Hidalgo and Anne Kim and Ansari, {M. Qasim}",
year = "2011",
month = "4",
doi = "10.1309/LMVS6PFQP97HIUYV",
language = "English (US)",
volume = "42",
pages = "209--212",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - The VITROS immunodiagnostics products anti-HIV 1+2 assay

T2 - A rapid and reliable method for HIV screening

AU - Thompson, Matthew P.

AU - Hidalgo, Darnely

AU - Kim, Anne

AU - Ansari, M. Qasim

PY - 2011/4

Y1 - 2011/4

N2 - Background: To ensure increased awareness of HIV status by patients, the Centers for Disease Control and Prevention (CDC) has issued new guidelines that greatly expand screening recommendations. The goal of the present study was to assess the overall reliability, sensitivity, specificity, and turnaround time (TAT) of the VITROS Anti-HIV 1+2 Assay (Ortho Clinical Diagnostics, Rochester, NY) in a large community hospital setting. The assay was recently approved by the Food and Drug Administration (FDA). Methods: We compared our current Abbott HIVAB assay (Abbott Laboratories, Abbott Park, IL) with how the VITROS performed on the random access VITROS ECi/ECiQ System in a head-to-head comparison of 298 patient samples and a retrospective comparison of TAT over an 8-month period of utilization. Results: Our data indicate that the VITROS is as sensitive (100%, n=298) and more specific (98% vs 83%) than the Abbott HIVAB and has a faster average TAT (156 minutes vs 1266 minutes). Conclusions: Use of this rapid and reliable assay will lead to greater awareness of HIV status and, hopefully, a decrease in incidence of HIV disease.

AB - Background: To ensure increased awareness of HIV status by patients, the Centers for Disease Control and Prevention (CDC) has issued new guidelines that greatly expand screening recommendations. The goal of the present study was to assess the overall reliability, sensitivity, specificity, and turnaround time (TAT) of the VITROS Anti-HIV 1+2 Assay (Ortho Clinical Diagnostics, Rochester, NY) in a large community hospital setting. The assay was recently approved by the Food and Drug Administration (FDA). Methods: We compared our current Abbott HIVAB assay (Abbott Laboratories, Abbott Park, IL) with how the VITROS performed on the random access VITROS ECi/ECiQ System in a head-to-head comparison of 298 patient samples and a retrospective comparison of TAT over an 8-month period of utilization. Results: Our data indicate that the VITROS is as sensitive (100%, n=298) and more specific (98% vs 83%) than the Abbott HIVAB and has a faster average TAT (156 minutes vs 1266 minutes). Conclusions: Use of this rapid and reliable assay will lead to greater awareness of HIV status and, hopefully, a decrease in incidence of HIV disease.

KW - HIV

KW - Rapid testing

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=79955526740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955526740&partnerID=8YFLogxK

U2 - 10.1309/LMVS6PFQP97HIUYV

DO - 10.1309/LMVS6PFQP97HIUYV

M3 - Article

AN - SCOPUS:79955526740

VL - 42

SP - 209

EP - 212

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 4

ER -